Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer

Abstract Development of chemoresistance and rapid inactivation of gemcitabine (Gem), the standard therapy for advanced pancreatic cancer, are responsible of the major therapeutic failures. To overcome the above drawbacks we designed a novel nanomedicine strategy for Gem nanoparticle (NP) formulation...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nanomedicine 2011-12, Vol.7 (6), p.841-849
Hauptverfasser:	Réjiba, Soukaina, PhD, Reddy, L. Harivardhan, PhD, Bigand, Christelle, MS, Parmentier, Céline, MS, Couvreur, Patrick, PhD, Hajri, Amor, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Animals Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - chemistry Antimetabolites, Antineoplastic - therapeutic use Apoptosis - drug effects Cell Line Cell Line, Tumor Chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - chemistry Deoxycytidine - therapeutic use Female Gemcitabine Gemcitabine-squalene Humans Internal Medicine Mice Mice, Nude Nanomedicine Nanoparticles Nanoparticles - chemistry Pancreas - drug effects Pancreas - pathology Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Squalene - administration & dosage Squalene - chemistry Squalene - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!